Acylation-stimulating protein precursor proteins in adipose tissue in human obesity (Q44621531)

4 December 2017

Acylation-stimulating protein precursor proteins in adipose tissue in human obesity (English)

1 reference

4 December 2017

0 references

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

22 March 2024

2

Katherine Cianflone

1 reference

4 December 2017

Zhunan Xia

1

1 reference

4 December 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14564690

22 March 2024

publication date

1 October 2003

1 reference

full work available at URL

4 December 2017

https://api.elsevier.com/content/article/PII:S0026049503002543?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

https://api.elsevier.com/content/article/PII:S0026049503002543?httpAccept=text/plain

22 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

22 March 2024

1 reference

4 December 2017

52

1 reference

4 December 2017

10

1 reference

4 December 2017

1360-1366

1 reference

Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Serum complement and familial combined hyperlipidemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Association of serum C3 levels with the risk of myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Serum C3 but not plasma acylation-stimulating protein is elevated in Finnish patients with familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Concentration of the complement activation product, acylation-stimulating protein, is related to C-reactive protein in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Insulin action and insulinemia are closely related to the fasting complement C3, but not acylation stimulating protein concentration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Effect of body weight and caloric restriction on serum complement proteins, including Factor D/adipsin: studies in anorexia nervosa and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Postprandial increase of complement component 3 in normolipidemic patients with coronary artery disease: effects of expanded-dose simvastatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Protein metabolism in obese patients during very low-calorie mixed diets containing different amounts of proteins and carbohydrates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Nitrogen economy during very low calorie reducing diets: quality and quantity of dietary protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Correlations between serum lipids and complement components in adults without demonstrated atherosclerotic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Disorders of the complement system in lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

The Complement Abnormalities of Lipodystrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Hypocomplementaemia caused by C3 nephritic factors (C3 NeF): clinical findings and the coincidence of C3 NeF type II with anti-C1q autoantibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Complements in diabetes mellitus: activation of complement system evidenced by C3d elevation in IDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

The relationship between serum levels of lipoprotein(a) and proteins associated with the acute phase response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Additive effect of diabetes and systemic hypertension on the immune mechanisms of atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Human C′3: Evidence for the Liver as the Primary Site of Synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Detection and quantification of the control proteins of the alternative pathway of complement in 3T3-L1 adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Differentiation-induced production of ASP in human adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Regulation of alternative pathway activation and C3a production by adipose cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Plasma acylation stimulating protein concentration and subcutaneous adipose tissue C3 mRNA expression in nondiabetic and type 2 diabetic men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Fasting and postprandial plasma concentrations of acylation-stimulation protein (ASP) in lean and obese Pima Indians compared to Caucasians.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

The influence of oral lipid loads on acylation stimulating protein (ASP) in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Impact of adipose tissue on plasma plasminogen activator inhibitor-1 in dieting obese women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Adipsin/acylation stimulating protein system in human adipocytes: regulation of triacylglycerol synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Differences in lipolysis between human subcutaneous and omental adipose tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Metabolic implications of body fat distribution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Increased expression of complement component C3 in the plasma of obese Zucker fa and LA/N fa(f) rats compared with their lean counterparts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Acylation stimulating protein (ASP), an adipocyte autocrine: new directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Mechanisms involved in the regulation of free fatty acid release from isolated human fat cells by acylation-stimulating protein and insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

The effect of ASP on the adipocyte of the morbidly obese

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Plasma acylation stimulating protein (ASP) as a predictor of impaired cellular biological response to ASP in patients with hyperapoB.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

Hyperapobetalipoproteinemia. Plasma lipoprotein responses to oral fat load.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900254-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunologic status in severe obesity

19

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

Association of serum C3 and essential hypertension

22 March 2024

22

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

Increased level of the complement C3 protein in endogenous hypertriglyceridemia

22 March 2024

23

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

Response of plasma ASP to a prolonged fast

22 March 2024

34

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass

22 March 2024

45

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

The regulation of adipose tissue distribution in humans

22 March 2024

51

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

Regional specificity of ASP binding in human adipose tissue

22 March 2024

59

1 reference

https://api.crossref.org/works/10.1016/S0026-0495(03)00254-3

22 March 2024

Identifiers

1 reference

4 December 2017

1 reference